One size does not always fit all in value assessment.

Laying a clear path for incorporating reliable evidence on heterogeneity in value assessments could improve their applicability for healthcare decision making.

[1]  L. Wilson,et al.  Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center. , 2017, Journal of managed care & specialty pharmacy.

[2]  Issa J Dahabreh,et al.  Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials. , 2016, International journal of epidemiology.

[3]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[4]  A. Kesselheim,et al.  The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. , 2016, JAMA.

[5]  Adam P Dicker,et al.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Karl Claxton,et al.  The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  J. Sekhon,et al.  Methods for Estimating Subgroup Effects in Cost-Effectiveness Analyses That Use Observational Data , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[8]  A. Basu.  Estimating Person-Centered Treatment (Pet) Effects Using Instrumental Variables , 2012, Journal of applied econometrics.

[9]  Anirban Basu,et al.  Economics of Individualization in Comparative Effectiveness Research and a Basis for a Patient-Centered Health Care , 2011, Journal of health economics.

[10]  A. Gafni,et al.  On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. , 2002, Health economics.

[11]  I. Christensen,et al.  Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. , 2010, Arthritis and rheumatism.